Prothena to Participate in JMP Securities Hematology and Oncology Summit
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
DUBLIN, Ireland, Nov. 29, 2021 – Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company, announced its senior management will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit on December 6, 2021, at 1:20 PM ET. A live webcast will be accessible on Prothena's investor relations site, with a replay available for at least 90 days post-event. Prothena focuses on investigational therapeutics targeting rare peripheral amyloid and neurodegenerative diseases, leveraging its expertise in protein dysregulation.
Details
News Market Reaction – PRTA
The recorded move for PRTA in the trading session of this news was +1.89%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DUBLIN, Ireland, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit on Monday December 6, 2021 at 1:20 PM ET.
A live webcast of the fireside chat can be accessed through the investor relations section of the Company's website at www.prothena.com. Following the live presentation, a replay of the webcast will be available on the Company's website for at least 90 days following the presentation date.
About Prothena
Prothena Corporation plc is a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise with the potential to change the course of devastating rare peripheral amyloid and neurodegenerative diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a number of other neurodegenerative diseases. For more information, please visit the Company’s website at www.prothena.com and follow the Company on Twitter @ProthenaCorp.
Investors & Media
Jennifer Zibuda, Director, Investor Relations & Communications
650-837-8535, jennifer.zibuda@prothena.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.